EndoC-βH1®
The human beta cell line of reference
FIRST VALIDATED HUMAN BETA CELL LINE
EndoC-βH1® is a robust and immortalized human beta cell line
This high-quality human pancreatic beta cell line displays a homogeneity that exceeds 99% and an insulin content of 0.5 to 1 µg/million cells. Functionality of EndoC-βH1® cells has been validated using glucose stimulated insulin secretion (GSIS) assay. Our production and assay processes are conducted with rigor and precision, in full respect of the industry’s highest quality standards for reliability and reproducibility. Below are the technical data of EndoC-βH1® characteristics.
HUMAN BETA CELLS IN UNLIMITED QUANTITIES
EndoC-βH1® is an amplifiable human pancreatic beta cell, while maintaining a significant level of function
ALREADY TESTED AND APPROVED BY MORE THAN
Academic & pharmaceutical laboratories worldwide
KEY BENEFITS
APPLICATIONS
TECHNOLOGY LIMITS
QUALITY ASSURANCE
Deposited cell line (Pasteur Institute CNCM)
Short Tandem Repeat analysis available
Functional validation (glucose and incretin)
Batch Release Certificates available
Negative for mycoplasma
FUNCTIONAL VALIDATION
Insulin content
EndoC-βH1® cell insulin content is about 10% that of native human beta cells (close to 1 μg insulin/million cells)
Glucose stimulated insulin secretion (GSIS)
EndoC-βH1® cells secrete insulin upon glucose stimulation and secretion is further potentiated by IBMX
In Vivo Validation
EndoC-βH1® cells restore normo-glycemia when transplanted into diabetic (STZ) SCID mice